Ritu Banerjee1, Christine B Teng2, Scott A Cunningham3, Sherry M Ihde3, James M Steckelberg4, James P Moriarty5, Nilay D Shah5, Jayawant N Mandrekar6, Robin Patel7. 1. Division of Pediatric Infectious Diseases, Mayo Clinic, Rochester, Minnesota. 2. Department of Pharmacy, National University of Singapore and Tan Tock Seng Hospital, Singapore. 3. Division of Laboratory Medicine and Pathology. 4. Division of Infectious Diseases. 5. Division of Health Care Policy and Research. 6. Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. 7. Division of Laboratory Medicine and Pathology Division of Infectious Diseases.
Abstract
BACKGROUND: The value of rapid, panel-based molecular diagnostics for positive blood culture bottles (BCBs) has not been rigorously assessed. We performed a prospective randomized controlled trial evaluating outcomes associated with rapid multiplex PCR (rmPCR) detection of bacteria, fungi, and resistance genes directly from positive BCBs. METHODS: A total of 617 patients with positive BCBs underwent stratified randomization into 3 arms: standard BCB processing (control, n = 207), rmPCR reported with templated comments (rmPCR, n = 198), or rmPCR reported with templated comments and real-time audit and feedback of antimicrobial orders by an antimicrobial stewardship team (rmPCR/AS, n = 212). The primary outcome was antimicrobial therapy duration. Secondary outcomes were time to antimicrobial de-escalation or escalation, length of stay (LOS), mortality, and cost. RESULTS: Time from BCB Gram stain to microorganism identification was shorter in the intervention group (1.3 hours) vs control (22.3 hours) (P < .001). Compared to the control group, both intervention groups had decreased broad-spectrum piperacillin-tazobactam (control 56 hours, rmPCR 44 hours, rmPCR/AS 45 hours; P = .01) and increased narrow-spectrum β-lactam (control 42 hours, rmPCR 71 hours, rmPCR/AS 85 hours; P = .04) use, and less treatment of contaminants (control 25%, rmPCR 11%, rmPCR/AS 8%; P = .015). Time from Gram stain to appropriate antimicrobial de-escalation or escalation was shortest in the rmPCR/AS group (de-escalation: rmPCR/AS 21 hours, control 34 hours, rmPCR 38 hours, P < .001; escalation: rmPCR/AS 5 hours, control 24 hours, rmPCR 6 hours, P = .04). Groups did not differ in mortality, LOS, or cost. CONCLUSIONS:rmPCR reported with templated comments reduced treatment of contaminants and use of broad-spectrum antimicrobials. Addition of antimicrobial stewardship enhanced antimicrobial de-escalation. CLINICAL TRIALS REGISTRATION: NCT01898208.
RCT Entities:
BACKGROUND: The value of rapid, panel-based molecular diagnostics for positive blood culture bottles (BCBs) has not been rigorously assessed. We performed a prospective randomized controlled trial evaluating outcomes associated with rapid multiplex PCR (rmPCR) detection of bacteria, fungi, and resistance genes directly from positive BCBs. METHODS: A total of 617 patients with positive BCBs underwent stratified randomization into 3 arms: standard BCB processing (control, n = 207), rmPCR reported with templated comments (rmPCR, n = 198), or rmPCR reported with templated comments and real-time audit and feedback of antimicrobial orders by an antimicrobial stewardship team (rmPCR/AS, n = 212). The primary outcome was antimicrobial therapy duration. Secondary outcomes were time to antimicrobial de-escalation or escalation, length of stay (LOS), mortality, and cost. RESULTS: Time from BCB Gram stain to microorganism identification was shorter in the intervention group (1.3 hours) vs control (22.3 hours) (P < .001). Compared to the control group, both intervention groups had decreased broad-spectrum piperacillin-tazobactam (control 56 hours, rmPCR 44 hours, rmPCR/AS 45 hours; P = .01) and increased narrow-spectrum β-lactam (control 42 hours, rmPCR 71 hours, rmPCR/AS 85 hours; P = .04) use, and less treatment of contaminants (control 25%, rmPCR 11%, rmPCR/AS 8%; P = .015). Time from Gram stain to appropriate antimicrobial de-escalation or escalation was shortest in the rmPCR/AS group (de-escalation: rmPCR/AS 21 hours, control 34 hours, rmPCR 38 hours, P < .001; escalation: rmPCR/AS 5 hours, control 24 hours, rmPCR 6 hours, P = .04). Groups did not differ in mortality, LOS, or cost. CONCLUSIONS: rmPCR reported with templated comments reduced treatment of contaminants and use of broad-spectrum antimicrobials. Addition of antimicrobial stewardship enhanced antimicrobial de-escalation. CLINICAL TRIALS REGISTRATION: NCT01898208.
Authors: J Garnacho-Montero; A Gutiérrez-Pizarraya; A Escoresca-Ortega; Y Corcia-Palomo; Esperanza Fernández-Delgado; I Herrera-Melero; C Ortiz-Leyba; J A Márquez-Vácaro Journal: Intensive Care Med Date: 2013-09-12 Impact factor: 17.440
Authors: Angela M Caliendo; David N Gilbert; Christine C Ginocchio; Kimberly E Hanson; Larissa May; Thomas C Quinn; Fred C Tenover; David Alland; Anne J Blaschke; Robert A Bonomo; Karen C Carroll; Mary Jane Ferraro; Lisa R Hirschhorn; W Patrick Joseph; Tobi Karchmer; Ann T MacIntyre; L Barth Reller; Audrey F Jackson Journal: Clin Infect Dis Date: 2013-12 Impact factor: 9.079
Authors: Katherine K Perez; Randall J Olsen; William L Musick; Patricia L Cernoch; James R Davis; Leif E Peterson; James M Musser Journal: J Infect Date: 2014-05-17 Impact factor: 6.072
Authors: Ricard Ferrer; Ignacio Martin-Loeches; Gary Phillips; Tiffany M Osborn; Sean Townsend; R Phillip Dellinger; Antonio Artigas; Christa Schorr; Mitchell M Levy Journal: Crit Care Med Date: 2014-08 Impact factor: 7.598
Authors: Katherine K Perez; Randall J Olsen; William L Musick; Patricia L Cernoch; James R Davis; Geoffrey A Land; Leif E Peterson; James M Musser Journal: Arch Pathol Lab Med Date: 2012-12-06 Impact factor: 5.534
Authors: Scott Fridkin; James Baggs; Ryan Fagan; Shelley Magill; Lori A Pollack; Paul Malpiedi; Rachel Slayton; Karim Khader; Michael A Rubin; Makoto Jones; Matthew H Samore; Ghinwa Dumyati; Elizabeth Dodds-Ashley; James Meek; Kimberly Yousey-Hindes; John Jernigan; Nadine Shehab; Rosa Herrera; Clifford L McDonald; Amy Schneider; Arjun Srinivasan Journal: MMWR Morb Mortal Wkly Rep Date: 2014-03-07 Impact factor: 17.586
Authors: Conner Sothoron; Jason Ferreira; Nilmarie Guzman; Petra Aldridge; Yvette S McCarter; Christopher A Jankowski Journal: J Clin Microbiol Date: 2015-08-19 Impact factor: 5.948
Authors: B Fiori; T D'Inzeo; A Giaquinto; G Menchinelli; F M Liotti; F de Maio; G De Angelis; G Quaranta; D Nagel; M Tumbarello; B Posteraro; M Sanguinetti; T Spanu Journal: J Clin Microbiol Date: 2015-12-16 Impact factor: 5.948
Authors: Matthew S Kelly; Doyle V Ward; Christopher J Severyn; Mehreen Arshad; Sarah M Heston; Kirsten Jenkins; Paul L Martin; Lauren McGill; Andre Stokhuyzen; Shakti K Bhattarai; Vanni Bucci; Patrick C Seed Journal: Biol Blood Marrow Transplant Date: 2019-07-18 Impact factor: 5.742
Authors: Mohammed J Al-Jaghbeer; Julie Ann Justo; William Owens; Joseph Kohn; P Brandon Bookstaver; Jennifer Hucks; Majdi N Al-Hasan Journal: Infection Date: 2018-05-11 Impact factor: 3.553